Bullous pemphigoid is an autoimmune subepidermal blistering dermatosis that is uncommon in childhood. We report a case of a female infant, 3 months old, which presented clinical and laboratory data ...

The differential diagnosis of dyshidrosis includes pustular psoriasis of the palms and soles, chronic vesicular hand dermatitis contact allergy, vesicular tinea pedis and tinea manus, scabies ...

Sanofi & Regeneron’s Dupixent receives US FDA approval to treat patients with bullous pemphigoid Paris Saturday, June 21, 2025, 12:00 Hrs [IST] The US Food and Drug Administration (FDA) has approved ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron ...

Alyssa Johnsen, MD, PhD, Global Therapeutic Area Head, Immunology and Oncology Development, Sanofi said, “Until now, treating bullous pemphigoid was very challenging for elderly patients struggling ...

Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent (dupilumab), for the treatment of adult patients with bullous pemphigoid (BP ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...

FDA approves Dupixent for treating bullous pemphigoid in adults, showing significant improvements in disease management. Quiver AI Summary The U.S. Food and Drug Administration (FDA) has approved ...

Bullous Pemphigoid: joint pain (arthralgia), eye problems, including eye and eyelid inflammation, redness, swelling, itching, and blurred vision, and herpes virus infections.

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic ...

The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease often uncontrolled with systemic corticosteroids, Sanofi and Regeneron announced. The FDA’s ...

Dupilumab, administered by subcutaneous injection, is the first targeted treatment to be approved in the United States for bullous pemphigoid, according to the company’s press release.